Company intelligence / Profile preview

Nielsen BioSciences, Inc.

San Diego, California, United Statesnielsenbio.com ↗

Ownership: Private
Employees: ~12
Development stage: Phase 3

Overview

Nielsen BioSciences markets two FDA-approved skin test antigens—CANDIN® and SPHERUSOL®—for assessing cell-mediated immunity to Candida albicans and Coccidioides immitis, respectively. The company is conducting a Phase 3 clinical trial evaluating CANDIN® as a treatment for common warts caused by HPV. These programs leverage the activation of cell-mediated immune responses to diagnose or potentially treat infectious diseases.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Biological products (antigen-based skin test antigens)Immunotherapies (cell-mediated immune response activators)
Industry: Biotech

Drug pipeline

5 assets

candida albicans antigen

Approved

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Nielsen BioSciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nielsen BioSciences, Inc..

Explore the full profile